Using biomarkers to improve treatment for high-risk bladder cancer
Official title: Biomarker guided combinations for treating high-risk bladder cancer
Funded at Augusta University · NIH-10883703 · Data updated 2026-11-12
This study is looking at new ways to help people with high-risk bladder cancer feel better by testing different combinations of chemotherapy drugs, including Gemcitabine, and finding out which treatments work best for them based on their unique needs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project start | July 5, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $529,168 |
| NIH project number | 5R01CA283699-02 |
| Project ID | NIH-10883703 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with high-grade muscle-invasive bladder cancer who are at risk for metastasis.
✕Less likely to help
Patients with low-grade bladder cancer or those who have already undergone extensive treatment may not benefit from this research.
What this research studies
This research focuses on improving treatment outcomes for patients with high-risk bladder cancer, particularly those with muscle-invasive bladder cancer (MIBC). The study evaluates two specific combinations of chemotherapy drugs, particularly Gemcitabine, to enhance effectiveness and reduce the risk of metastasis. It aims to identify biomarkers that can guide treatment decisions, potentially leading to more personalized and effective therapies. By understanding the mechanisms of drug resistance, the research seeks to optimize treatment protocols for better patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for high-risk bladder cancer, potentially reducing recurrence and improving survival rates.
How similar studies have gone: Previous research has shown promise in using biomarker-guided therapies for other cancers, suggesting potential success for this novel approach in bladder cancer.
Where this research is happening
-
Augusta University
Augusta, United States Active
Researchers
- Principal investigator: Lokeshwar, Vinata B — Augusta University
- Study coordinator: Lokeshwar, Vinata B
Related research
Other NIH-funded projects on the same topics.
-
Population modeling to reduce bladder cancer burden
Aimed at predicting and guiding effective, population-based ways to prevent and control bladder cancer.
-
Blocking a new immune checkpoint in bladder cancer
Researchers are trying medicines that block a newly found immune pathway to help people with bladder cancer, especially those whose tumors do not respond to current immunotherapy.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Understanding why bladder cancer spreads and resists treatment
This grant studies how advanced bladder cancer changes and spreads across the body, aiming to uncover why it’s hard to treat.
-
Molecular clues to bladder cancer cell changes and therapy response
This NIH grant looks at how bladder cancer cells change their identity and how that affects response to treatment, with a focus on aggressive neuroendocrine variants.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.